Exchange: NASDAQ·Updated 07:31 PM EDT
NYXH logo

NYXH Nyxoah SA

$1.10
$0.08
(6.72%)
Today
Closed $1.11
$0.0093
(0.84%)
After Hours
EarningsNov 5
Mkt Cap$113.04M
Vol212,058.00

About NYXH

Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). Its solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe OSA. The company was founded by Robert Taub and Adi Mashiach on July 15, 2009, and is headquartered in Mont-Saint-Guibert, Belgium.
56

Bullish Sentiment

How do you feel about NYXH?

Merlintrader
Latest company news, October 15, 2026: Nyxoah presented full 12-month ACCCESS data in complete concentric collapse patients at ISSS 2026: 77.2% AHI responder rate, 74.3% median AHI reduction (per-protocol), no device- or procedure-related serious adverse events. It also submitted a PMA supplement asking the FDA to extend Genio to these patients. $NYXH Details on our site. Not investment advice.
3
Lilingpeace
$NYXH Such great news, but market has no reaction! Unbelievable!! CCC patients are contraindicated by Inspire device. This is huge for Genio!
2
Lilingpeace
$NYXH Many people do not realize how big the deal is to have CCC indication for Genio device. This stock is so unbelievably undervalued. I have loaded a lot more today.
1
Denzerini
$NYXH Someone doesn’t like the CFO turnover. I suspect that the handwriting was on the wall that when a new CEO gets hired, this individual will want to bring on their own executive team. We’ll see.
1
Gregg617
$NYXH I’ve been watching the Stock for years. I’m in my first purchase Friday at the close. We need to get market exposure to finally get moving again
topstockalerts
Nyxoah said CFO John Landry will leave on Oct. 2, 2026, to pursue another professional opportunity. Loïc Moreau, the company’s international president and former CFO, will serve as interim CFO while Nyxoah searches for a permanent successor. Moreau joined Nyxoah in 2022 as CFO and became international president in 2024. He has more than 20 years of finance experience, including senior roles at GSK in M&A and corporate development and country CFO positions across multiple markets. Despite the leadership change, Nyxoah reaffirmed its 2026 guidance, expecting global net revenue of €36 million-€40 million, gross margin of 60%-62%, total operating expenses of €99 million-€102 million and non-GAAP cash operating expenses of €88 million-€90 million. Its flagship Genio system is a wireless, battery-free hypoglossal nerve stimulation therapy for obstructive sleep apnea. $NYXH

Advertisement|Remove ads.